Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00600821 · ClinicalTrials.gov registry record · Phase 2

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

A Phase 2 study of Non-Small-Cell Lung Carcinoma and Adenocarcinoma, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
118
Enrollment target
20
Study locations

NCT00600821 is a Phase 2 study of Non-Small-Cell Lung Carcinoma and Adenocarcinoma that has completed, run by Pfizer. The registered enrollment target is 118 participants, below the 232-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00600821, a Phase 2 study of Non-Small-Cell Lung Carcinoma and Adenocarcinoma, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
118 participants
Enrollment target
20
Study locations

Study Summary

To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.

Conditions Studied

Non-Small-Cell Lung Carcinoma Adenocarcinoma

Interventions

  • DRUG Bevacizumab
  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG AG-013736 (axitinib)

Study Locations (20)

Mississippi

  • Pfizer Investigational Site - Columbus
  • Pfizer Investigational Site - Corinth
  • Pfizer Investigational Site - New Albany
  • Pfizer Investigational Site - Oxford
  • Pfizer Investigational Site - Southaven
  • Pfizer Investigational Site - Tupelo

Texas

  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Lubbock
  • Pfizer Investigational Site - San Antonio

Tennessee

  • Pfizer Investigational Site - Bartlett
  • Pfizer Investigational Site - Germantown
  • Pfizer Investigational Site - Memphis
  • Pfizer Investigational Site - Memphis

Louisiana

  • Pfizer Investigational Site - Baton Rouge

Massachusetts

  • Pfizer Investigational Site - Pittsfield

Nebraska

  • Pfizer Investigational Site - Lincoln

Ohio

  • Pfizer Investigational Site - Cleveland

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 2008-04
Est. Completion 2012-10
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00600821

The ClinicalTrials.gov registry entry for NCT00600821 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (49% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.

NCT00600821 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Mississippi, Texas, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00600821 about?

NCT00600821 is a clinical study titled "A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.". To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.

What is the current status of trial NCT00600821?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2008-04. Estimated completion is 2012-10.

What conditions does trial NCT00600821 study?

This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma.

What interventions are being tested in trial NCT00600821?

The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), AG-013736 (axitinib) (DRUG).

Who is sponsoring clinical trial NCT00600821?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00600821 being conducted?

This trial has 20 study locations across Louisiana, Massachusetts, Mississippi, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small-Cell Lung Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small-Cell Lung Carcinoma

All registered trials for this condition

Adenocarcinoma

All registered trials for this condition

Louisiana

All trials with a study site in Louisiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.